Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG MIX 75 25 KWIKPEN versus NOVOLOG INNOLET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG MIX 75 25 KWIKPEN versus NOVOLOG INNOLET.
HUMALOG MIX 75/25 KWIKPEN vs NOVOLOG INNOLET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by promoting peripheral glucose uptake (especially in muscle and adipose tissue) and inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase signaling pathways.
Insulin aspart is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase activity, which leads to glucose transporter translocation and metabolic effects.
Subcutaneous injection, individualized based on metabolic needs. Typical adult dose: 0.5-1.0 units/kg/day divided into preprandial doses. Administer within 15 minutes before a meal.
Subcutaneous injection, 0.5-1.0 unit/kg/day in divided doses, with meals.
None Documented
None Documented
4-6 minutes for insulin lispro (rapidly absorbed and cleared); terminal elimination half-life of insulin lispro is approximately 1 hour (reflecting dissociation from insulin receptors). Clinical context: the brief half-life allows for rapid dose adjustments and reduced risk of late hypoglycemia.
Terminal half-life: 81 minutes (range 70–90 minutes) for subcutaneous administration; reflects absorption-rate limited elimination
Renal: 100% (metabolized to inactive metabolites; metabolites excreted via kidneys). Biliary/fecal: negligible.
Renal: approximately 30% of total clearance as unchanged drug; hepatobiliary/fecal: minor (less than 1%)
Category C
Category C
Insulin Analog
Insulin Analog